These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 812544)
21. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165 [TBL] [Abstract][Full Text] [Related]
22. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa. Mates A; Zand P J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979 [TBL] [Abstract][Full Text] [Related]
23. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection. Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634 [TBL] [Abstract][Full Text] [Related]
24. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine. Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894 [TBL] [Abstract][Full Text] [Related]
25. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346 [TBL] [Abstract][Full Text] [Related]
26. [Use of polyvalent vaccine against Pseudomonas aeruginosa in extensive burns]. Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W Pol Tyg Lek; 1981 Aug; 36(32):1207-11. PubMed ID: 6798556 [No Abstract] [Full Text] [Related]
27. A new polyvalent Pseudomonas vaccine. Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473 [TBL] [Abstract][Full Text] [Related]
28. A new Pseudomonas vaccine: preliminary trial on human volunteers. Jones RJ; Roe EA; Lowbury EJ; Miler JJ; Spilsbury JF J Hyg (Lond); 1976 Jun; 76(3):429-39. PubMed ID: 819576 [TBL] [Abstract][Full Text] [Related]
29. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598 [TBL] [Abstract][Full Text] [Related]
30. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa. Ding B; von Specht BU; Li Y Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804 [TBL] [Abstract][Full Text] [Related]
32. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Neely AN; Holder IA; Wiener-Kronish JP; Sawa T Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685 [TBL] [Abstract][Full Text] [Related]
33. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine. Jones RJ; Hall M; Ricketts CR Immunology; 1972 Dec; 23(6):889-95. PubMed ID: 4630781 [TBL] [Abstract][Full Text] [Related]
34. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin]. Moroz AF; Kharitonova AM; Chanturiia TsK Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985 [TBL] [Abstract][Full Text] [Related]
35. Some biological and immunological properties of extracellular slime from Pseudomonas aeruginosa. Maresz-Babczyszyn J; Sokalska M Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):255-60. PubMed ID: 107919 [TBL] [Abstract][Full Text] [Related]
36. Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice. Kawaharajo K; Homma JY Jpn J Exp Med; 1977 Dec; 47(6):495-500. PubMed ID: 416253 [TBL] [Abstract][Full Text] [Related]
37. Preparation and assay of horse anti-Pseudomonas serum and -globulin in mice. Laborde HF; De Fajardo CL Prog Immunobiol Stand; 1971; 5():419-24. PubMed ID: 4633969 [No Abstract] [Full Text] [Related]
38. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections. Sourek J Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656 [TBL] [Abstract][Full Text] [Related]
39. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland]. Bukowska D; Serafińska D; Zietkiewicz W; Rudowski W; Hoffman S; Uszyński H; Molski M; Hess C; Jonecko A; Popiel D Pol Tyg Lek; 1986 Dec; 41(49):1549-52. PubMed ID: 3108869 [No Abstract] [Full Text] [Related]
40. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)]. Daoulas-Le Bourdelles F; Berche P; Véron M Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]